The earliest preclinical studies were conducted with CAR T cells targeting EGFRvIII, IL13Ra2, and HER2 and had impressive rates of tumor control and improved survival in murine models [47,49,50,67,80], leading to the design of multiple clinical trials. This evidence concerns the gene ERBB2 and neoplasm.